Sorrento Therapeutics (NASDAQ: SRNE) has confirmed that it will release its Q4 2021 earnings report on Friday, March 18, 2022, during market hours.
What to look for
Earnings: Stockearning’s Estimated EPS for the quarter is expected to be $0.30 per share. In the third quarter, the company missed earnings estimates by 90.48%, with an actual loss per share of $0.4 missing on an estimated EPS loss of $0.21. for the full year ended December 31, 2021, the company reported a net loss per share of $1.45 compared to $1.3 a year before. On a per diluted share basis, the loss was $1.45 compared to a loss per share of $1.3 a year before. Historical EPS Performance shows that the company has, in the past 12 quarters, topped estimates seven times (20%), matched two times, and missed 15 times (42%).
Revenue: For the fourth quarter, the company expects to post sales of $15.13 million compared to sales of $11.51 million in the fourth quarter of 2020, which implies a YoY growth of 31.5%. The company had revenue of $52.9 million for the full year ended December 31, 2021, with a net loss of $428.33 million. Sorrento expects full-year revenue of $54.96 million for this year, and for the next financial year, the company expects sales to be around $103.2 million
Stock Movement: SRNE shares have lost 69.8% since the company released its last earnings release. Interestingly, following the earnings release, the company's shares have been DOWN 13 times in the past 23 quarters. So, the historical price reaction suggests a 56% probability of the share price going DOWN following the earnings release. According to the Stockearning algorithm, the predicted volatility on the first day is +/-4%, while the predicted volatility on the seventh day is +/-19%.
What analysts are saying: H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating in the stock with a price target of $26 after the firm announced that the preliminary testing of Covistix on recombinant N proteins showed the ability of the rapid test in detecting Omicron variant. Selvaraju informs investors in a research note that Sorrento has the potential to generate 30 million Covistix tests per month and is expanding its production capacity in the United States. According to the expert, depending on US and worldwide demand, the capacity might be increased to above 100M monthly by 2022. considering the recent upticks in COVID-19 instances across the globe, Selvaraju predicts that the company will remain a relevant stock.
Related News
Vail Resort Inc. (NASDAQ: MTN) Earnings Expectation, Fiscal Q2 2022 EPS of $5.73 on revenue of $966.3 Million
Oracle Corporation (NYSE: ORCL) Misses Q3 2022 Earnings But Matches Revenue Estimates